Orelabrutinib
- Generic Name
- Orelabrutinib
- Drug Type
- Small Molecule
- Chemical Formula
- C26H25N3O3
- CAS Number
- 1655504-04-3
- Unique Ingredient Identifier
- WJA5UO9E10
- Background
Orelabrutinib is under investigation in clinical trial NCT04305197 (A Study of ICP-022 in Patients With Systemic Lupus Erythematosus (SLE)).
- Indication
⑴既往至少接受过一种治疗的成人套细胞淋巴瘤（MCL）患者。
⑵既往至少接受过一种治疗的成人慢性淋巴细胞白血病（CLL）/小淋巴细胞淋巴瘤（SLL）患者。
Orelabrutinib Maintenance Therapy After ASCT in Primary Central Nervous System Lymphoma
- First Posted Date
- 2022-04-19
- Last Posted Date
- 2022-04-19
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 174
- Registration Number
- NCT05334238
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai, Shanghai, China
Orelabrutinib and Obinutuzumab Plus FC Regimen in Treating Newly Diagnosed CLL/SLL
- Conditions
- Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Interventions
- First Posted Date
- 2022-04-12
- Last Posted Date
- 2022-04-19
- Target Recruit Count
- 25
- Registration Number
- NCT05322733
- Locations
- 🇨🇳
Department of Haematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjin, Jiangsu, China
DDI Study of Orelabrutinib
- Conditions
- Healthy Person
- Interventions
- First Posted Date
- 2022-04-07
- Last Posted Date
- 2022-07-06
- Lead Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
- Target Recruit Count
- 36
- Registration Number
- NCT05316857
- Locations
- 🇨🇳
The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
A Study of Orelabrutinib in Patients With AQP4-IgG Positive Neuromyelitis Optica Spectrum Disorder
- First Posted Date
- 2022-03-17
- Last Posted Date
- 2022-03-17
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 23
- Registration Number
- NCT05284175
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With MCD Subtype Diffuse Large B-cell Lymphoma
- Conditions
- Diffuse Large B Cell Lymphoma (DLBCL)
- Interventions
- Drug: Placebo + R-CHOP
- First Posted Date
- 2022-02-10
- Last Posted Date
- 2024-02-07
- Lead Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
- Target Recruit Count
- 150
- Registration Number
- NCT05234684
- Locations
- 🇨🇳
PEKING University SHENZHEN Hospital, Shenzhen, Guangdong, China
🇨🇳Sun Yat-sen University Cancer Center Internal medicine department, Guandong, Guangzhou, China
🇨🇳Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Orelabrutinib Combined With Pemetrexed For Relapsed/Refractory Central Nervous System Lymphoma
- Conditions
- Central Nervous System Lymphoma
- Interventions
- First Posted Date
- 2022-01-26
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT05209620
- Locations
- 🇨🇳
Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university, Zhengzhou, Henan, China
A Study of Orelabrutinib in Patients With ITP
- First Posted Date
- 2021-11-17
- Last Posted Date
- 2021-11-17
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 10
- Registration Number
- NCT05124028
- Locations
- 🇨🇳
Peking University Institute of Hematology, Beijing, Beijing, China
A Study of OLR in First-line Treatment of Mantle Cell Lymphoma
- Conditions
- Mantle Cell Lymphoma
- Interventions
- First Posted Date
- 2021-10-13
- Last Posted Date
- 2021-11-11
- Target Recruit Count
- 29
- Registration Number
- NCT05076097
- Locations
- 🇨🇳
Tianjin Medical University Cancer Insititute & Hospital, Tianjin, Tianjin, China
A Randomized, Open-label, Multi-center, Phase III Study of Orelabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) vs. R-CHOP Alone in Patients With Treatment-naїve Mantle Cell Lymphoma
- Conditions
- Treatment-naїve Mantle Cell Lymphoma
- Interventions
- Drug: R-CHOP
- First Posted Date
- 2021-09-21
- Last Posted Date
- 2022-10-12
- Lead Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
- Target Recruit Count
- 356
- Registration Number
- NCT05051891
- Locations
- 🇨🇳
The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China
🇨🇳Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
🇨🇳Guangzhou First People's Hospital, Guangzhou, Guangdong, China
A Dose-escalating Pilot Study of Orelabrutinib for Newly-diagnosed PCNSL
- Conditions
- Primary Central Nervous System Lymphoma
- Interventions
- First Posted Date
- 2021-09-05
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- Huashan Hospital
- Target Recruit Count
- 15
- Registration Number
- NCT05036577
- Locations
- 🇨🇳
Department of Hematology, Huashan Hospital, Fudan University, Shanghai, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.